標(biāo)題: Titlebook: Breast Disease; Management and Thera Adnan Aydiner,Abdullah Igci,Atilla Soran Book 2019Latest edition Springer Nature Switzerland AG 2019 b [打印本頁(yè)] 作者: Weber-test 時(shí)間: 2025-3-21 17:44
書目名稱Breast Disease影響因子(影響力)
書目名稱Breast Disease影響因子(影響力)學(xué)科排名
書目名稱Breast Disease網(wǎng)絡(luò)公開度
書目名稱Breast Disease網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Breast Disease被引頻次
書目名稱Breast Disease被引頻次學(xué)科排名
書目名稱Breast Disease年度引用
書目名稱Breast Disease年度引用學(xué)科排名
書目名稱Breast Disease讀者反饋
書目名稱Breast Disease讀者反饋學(xué)科排名
作者: ACRID 時(shí)間: 2025-3-21 22:18 作者: 顯赫的人 時(shí)間: 2025-3-22 01:53 作者: 制造 時(shí)間: 2025-3-22 06:22
http://image.papertrans.cn/b/image/190593.jpg作者: 違抗 時(shí)間: 2025-3-22 10:12 作者: COMA 時(shí)間: 2025-3-22 15:54
Jianquan Zhou,Yi Gao,Siyu Zhangto axillary surgery for SLNB or ALND or to neoadjuvant chemotherapy in those with axillary node-positive disease. However, there is no perfect modality to identify metastatic disease in breast cancer; every diagnostic test has its own advantages and limitations. The available evidence suggests routi作者: offense 時(shí)間: 2025-3-22 18:07
Man-Machine Speech Communication prognosis of patients with newly diagnosed breast cancer. According to the seventh revised edition of the TNM system in 2009, the presence of isolated tumor cells (ITCs) or micrometastases in axillary lymph nodes has little impact on survival. Furthermore, due to the increasing application of neoad作者: 辯論 時(shí)間: 2025-3-22 22:44
Rui Liu,Feilong Bao,Guanglai Gao,Yonghe Wang population-based screening programs, increased awareness, and improved visualization techniques are powerful tools for the early and more precise evaluation and early diagnosis of breast cancer (BC). Optimally timed and safe surgical approaches are needed to provide local control with satisfactoril作者: Minikin 時(shí)間: 2025-3-23 05:22 作者: 四海為家的人 時(shí)間: 2025-3-23 08:07 作者: jocular 時(shí)間: 2025-3-23 11:57 作者: CHOKE 時(shí)間: 2025-3-23 16:03 作者: 具體 時(shí)間: 2025-3-23 18:29 作者: lanugo 時(shí)間: 2025-3-24 00:17 作者: Glycogen 時(shí)間: 2025-3-24 04:48 作者: GORGE 時(shí)間: 2025-3-24 07:44 作者: 消音器 時(shí)間: 2025-3-24 14:07
Chenming Li,Tianhao Wang,Yuhong Shenr. PSC has evolved as an integral part of the multidisciplinary treatment approach for breast cancer and has a long history that dates back nearly four decades. Despite previous beliefs that it is more suitable for locally advanced or inflammatory disease, PSC is becoming increasingly popular in the作者: 煤渣 時(shí)間: 2025-3-24 15:30 作者: 北極熊 時(shí)間: 2025-3-24 21:48 作者: ambivalence 時(shí)間: 2025-3-25 02:38 作者: Outmoded 時(shí)間: 2025-3-25 05:48
Breast Reconstructionisions regarding the timing, type, and extent of reconstruction. The gold standard for breast cancer care includes an integrated multidisciplinary team approach, comprising surgical oncologists, medical oncologists, radiation oncologists, oncology nurses, and plastic surgeons.作者: 混沌 時(shí)間: 2025-3-25 08:47 作者: 友好 時(shí)間: 2025-3-25 14:47 作者: refraction 時(shí)間: 2025-3-25 17:47
Man-Machine-Environment System Engineeringisions regarding the timing, type, and extent of reconstruction. The gold standard for breast cancer care includes an integrated multidisciplinary team approach, comprising surgical oncologists, medical oncologists, radiation oncologists, oncology nurses, and plastic surgeons.作者: 嬰兒 時(shí)間: 2025-3-25 20:23
Shengzhao Long,Balbir S. Dhillon patients with ≥4 positive axillary lymph nodes but not given for most women with node-negative disease. Patients with one to three positive axillary lymph nodes constitute a gray zone. PMRT indications and side effects will be discussed in this chapter.作者: saturated-fat 時(shí)間: 2025-3-26 00:31 作者: Glaci冰 時(shí)間: 2025-3-26 04:35 作者: 埋伏 時(shí)間: 2025-3-26 10:52 作者: implore 時(shí)間: 2025-3-26 16:05 作者: CURL 時(shí)間: 2025-3-26 19:25
Dongdong Lu,Jun Zhang,Haiyang Gao,Chuang Liuantages and biological implications. The convenience of this method may facilitate patient acceptance and compliance with radiation therapy. Irradiating only the tumor-bearing quadrant of the breast in one to ten fractions instead of irradiating the whole breast after BCS has also increased in popularity recently.作者: orient 時(shí)間: 2025-3-26 22:40
Evaluation of Patients for Metastases Prior to Primary Therapys in breast cancer patients is by patient signs and symptoms including history and physical examination, laboratory tests, imaging, biopsy of suspicious finding in imaging studies, and monitoring serum markers.作者: 袖章 時(shí)間: 2025-3-27 04:22 作者: carotenoids 時(shí)間: 2025-3-27 06:26
Biopsy Techniques in Nonpalpable or?Palpable Breast Lesionsassic surgical incisional and excisional biopsies. Fine-needle aspiration (FNA) has an important historical role and remains among the most cost-effective methods but is limited by the weakness of current breast cytology to adequately reproduce all information provided by traditional histopathology.作者: Nebulizer 時(shí)間: 2025-3-27 10:11
Evaluation of Patients for Metastases Prior to Primary Therapyto axillary surgery for SLNB or ALND or to neoadjuvant chemotherapy in those with axillary node-positive disease. However, there is no perfect modality to identify metastatic disease in breast cancer; every diagnostic test has its own advantages and limitations. The available evidence suggests routi作者: 紋章 時(shí)間: 2025-3-27 16:22
Breast Cancer Staging prognosis of patients with newly diagnosed breast cancer. According to the seventh revised edition of the TNM system in 2009, the presence of isolated tumor cells (ITCs) or micrometastases in axillary lymph nodes has little impact on survival. Furthermore, due to the increasing application of neoad作者: Esalate 時(shí)間: 2025-3-27 21:39 作者: antiandrogen 時(shí)間: 2025-3-27 22:51 作者: GUISE 時(shí)間: 2025-3-28 05:31 作者: 座右銘 時(shí)間: 2025-3-28 06:19
Adjuvant Systemic Therapy: Endocrine Therapy5% of all breast cancers. Adjuvant endocrine therapy is a pivotal component of treatment for women with hormone receptor-positive early-stage breast cancer; it delays local and distant relapse and prolongs survival. Patients with ER- and/or PR-positive invasive breast cancers should be considered fo作者: single 時(shí)間: 2025-3-28 12:48
Adjuvant Systemic Chemotherapy for HER2-Negative Diseasepy. All patients with invasive breast cancer should be evaluated to assess the need for adjuvant cytotoxic therapy, trastuzumab, and/or endocrine therapy. If patients must receive endocrine therapy (either tamoxifen or aromatase inhibitor) and cytotoxic therapy as adjuvant therapy, chemotherapy shou作者: 宣傳 時(shí)間: 2025-3-28 14:50 作者: 江湖郎中 時(shí)間: 2025-3-28 22:12 作者: 禍害隱伏 時(shí)間: 2025-3-29 00:24 作者: 疼死我了 時(shí)間: 2025-3-29 06:04 作者: AMPLE 時(shí)間: 2025-3-29 10:04 作者: Infraction 時(shí)間: 2025-3-29 15:11
Neoadjuvant Hormonal Therapy in Breast Cancernt of locally advanced breast cancer, there are two options: chemotherapy or hormonal therapy. Chemotherapy can be toxic for postmenopausal elderly patients, and neoadjuvant hormonal therapy is an option for hormone receptor-positive locally advanced postmenopausal breast cancer. Such a treatment is作者: 中子 時(shí)間: 2025-3-29 19:13 作者: 不能逃避 時(shí)間: 2025-3-29 23:07 作者: BRINK 時(shí)間: 2025-3-30 01:13
Pingyue Zhang,Mengyue Wu,Kai Yu benign lesions or when coring biopsy tools fail to provide adequate diagnostic information and material. Ductoscopy, which was initially developed as a tool to investigate pathological nipple discharge, is an evolving technology that may have an increasing role in research and prevention, as tools 作者: AVOID 時(shí)間: 2025-3-30 06:11
Man-Machine Speech Communicationne prognostic signature or Oncotype DX tests may provide additional prognostic and predictive information beyond anatomic TNM staging and the estrogen receptor/progesterone receptor (ER/PR) and human epidermal growth factor receptor-2 (HER-2) status. In 2017, the eighth revised edition of the TNM sy作者: 調(diào)整 時(shí)間: 2025-3-30 10:52
Rui Liu,Feilong Bao,Guanglai Gao,Yonghe Wange “oncoplastic breast surgery (OBS)” concept has come into consideration among breast surgeons in the last two decades. The aim of OBS is to make no compromise from oncologic principles for a better cosmetic result. The tumor cavity is filled with the remaining breast tissue (volume displacement tec作者: 進(jìn)步 時(shí)間: 2025-3-30 15:27
Research on Telegrapher Selectionaxilla can become negative in up to 60% of cases depending on tumor biology, and SLNB can be performed with a low false-negative rate either using the targeted (clip-seed) technique or in the classic fashion (lympho-blue dye). In patients with positive SLNB (with limited involvement) after neoadjuva作者: 仲裁者 時(shí)間: 2025-3-30 16:53
Haijing Song,Li Han,Hongjiao Wus with tamoxifen in premenopausal and postmenopausal women, lowering systemic estrogen levels with luteinizing hormone-releasing hormone agonists in premenopausal women, or blocking estrogen biosynthesis in nonovarian tissues with aromatase inhibitors in postmenopausal women.作者: Harrowing 時(shí)間: 2025-3-30 21:23
Man-Machine-Environment System Engineeringgimen depends on the intrinsic subtype. Multigene expression array profiling is not always required for subtype definition after clinicopathological assessment. Young age, grade 3 disease, lymphovascular invasion, one to three positive nodes, and large tumor size are not adequate features to omit mo作者: drusen 時(shí)間: 2025-3-31 03:54
Shengzhao Long,Balbir S. Dhillonnts with HER-2-positive early breast cancer. Thus, the monoclonal antibody trastuzumab has been approved as the first and only molecularly targeted agent for the adjuvant treatment of HER-2-positive breast cancer. Despite tremendous progress in the treatment of HER-2-positive breast cancer, many que作者: ALB 時(shí)間: 2025-3-31 09:02 作者: coddle 時(shí)間: 2025-3-31 12:41
Chenming Li,Tianhao Wang,Yuhong ShenC provides an ideal setting in which the responsiveness of a given treatment can be observed and provides relevant information on the biology of the tumor by enabling biomarker analysis. Accumulating data on the strong association with survival and pathological complete response (pCR) may lead to a 作者: 同義聯(lián)想法 時(shí)間: 2025-3-31 16:14
